怀孕前,怀孕期间和怀孕后使用ADHD药物的轨迹:来自挪威和瑞典的基于人口的研究
Chaitra Srinivas1,2,3, Øystein Karlstad1, Hein Stigum3,4
1Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway.
Pharmacoepidemiology and drug safety
|June 13, 2023
概括
大多数孕妇停止服用ADHD药物,但近年来更多的孕妇继续服用. 延续者往往有过先前的分娩,可能有并发症,大多数人在怀孕期间减少剂量.
科学领域:
- 生殖健康 生殖健康
- 药理学 药理学 是一个学科.
- 神经科学是一个神经科学.
背景情况:
- 注意缺陷/多动障碍 (ADHD) 通常需要长期的药物管理.
- 了解怀孕期间的药物使用模式对于母亲和胎儿的健康至关重要.
- 以前关于怀孕期间使用ADHD药物的研究是有限的,特别是在北欧人口中.
研究的目的:
- 描述挪威和瑞典孕妇注意力缺陷/多动症 (ADHD) 药物使用的发展轨迹.
- 在怀孕前,怀孕期间和怀孕后识别ADHD药物使用的不同模式.
主要方法:
- 利用挪威 (2006-2019) 和瑞典 (2007-2018) 的链接的国家卫生登记册.
- 包括超过200万例怀孕,重点关注有ADHD药物处方的妇女.
- 采用基于群体的轨迹建模来识别药物使用模式.
主要成果:
- 确定了四种ADHD药物使用轨迹:持续者 (5.7%),中断者 (23.8%),停止者 (49.5%) 和晚期发起者 (21.0%).
- 停产者比较年轻,而继续停产者比较年长,更有可能有过以前的分娩.
- 近年来 (2014-2019) 更多的女性继续服用多动症药物,大多数持续者在怀孕期间降低了剂量.
结论:
- 大多数患有多动症的孕妇停止或中断服用药物,尽管继续治疗的比例正在增加.
- 在怀孕期间继续服用多动症治疗的妇女的特点是以前的分娩和潜在的并发症等因素.
- 大多数继续服用ADHD药物的女性在怀孕期间减少剂量,建议采取剂量调整策略.
相关概念视频
Attention-Deficit/Hyperactivity Disorder
133
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
133
Regression Toward the Mean
6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
211
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
211
Factors Affecting Drug Response: Overview
2.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.0K
Pharmacovigilance
914
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
914


